

*Claims*

1. A  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts of omeprazole and of esomeprazole, wherein  $\text{R}_1$  is a linear, branched  $\text{C}_1\text{-C}_{12}$ -alkyl group, or a cyclic  $\text{C}_3\text{-C}_{12}$ -alkyl; wherein the linear or branched alkyl group may be substituted or interrupted with a cyclic  $\text{C}_3\text{-C}_6$ -alkyl or alkylene group or with a phenyl or phenylene group; and wherein the cyclic alkyl or alkylene group or the phenyl or phenylene group is further substituted by 0, 1, 2, 3 methyl groups; and  $\text{R}_2$  and  $\text{R}_3$  are hydrogen.
2. The  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts of omeprazole and of esomeprazole according to claim 1 wherein the  $\text{R}_1$  is selected from linear, branched or cyclic  $\text{C}_1\text{-C}_6$ -alkyl group wherein the linear or branched alkyl group may be substituted or interrupted with a cyclic  $\text{C}_3\text{-C}_5$ -alkyl or alkylene group or with a phenyl or phenylene group; and wherein the cyclic alkyl or alkylene group or the phenyl or phenylene group is further substituted by 0, 1, 2, 3 methyl groups.
3. The  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts of omeprazole and of esomeprazole according to any of claims 1 or 2 wherein the  $\text{R}_1$  is selected from linear, branched or cyclic  $\text{C}_4$ -alkyl group wherein the linear or branched alkyl group may be substituted or interrupted with a cyclic  $\text{C}_3$ -alkyl or alkylene group; and wherein the cyclic alkyl or alkylene group is further substituted by 0, 1, 2, 3 methyl groups.
4. The  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts of omeprazole and of esomeprazole according to any of claims 1 or 3 wherein  $\text{NHR}_1\text{R}_2\text{R}_3^+$  has a pKa value equal or above 10.
5. The  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts of omeprazole and of esomeprazole according to any of claims 1 or 4 wherein  $\text{NHR}_1\text{R}_2\text{R}_3^+$  has a pKa value equal or above 10.5.
6. The  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts according to any of claims 1 to 5 characterized in that it is the  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salt of omeprazole.

7. The  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts according to any of claims 1 to 5 characterized in that it is the  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salt of esomeprazole.

8. The  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts according to claim 6 characterized in that it is the *tert*-butylammoniumsalt of omeprazole.

9. The  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts according to claim 7 characterized in that it is the *tert*-butylammoniumsalt of esomeprazole.

10. The  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salts according to any of the claims 1 to 9 characterized in that the compound is crystalline.

11. A process for preparation of a  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salt of omeprazole and of esomeprazole, according to any of claims 1 to 10, which comprises the following steps:

- a) dissolving omeprazole or esomeprazole in an organic solvent;
- b) adding a  $\text{NR}_1\text{R}_2\text{R}_3$ -compound and precipitating the desired salt;
- c) isolating and drying of the obtained salt of omeprazole or esomeprazole.

12. The process according to claim 11 wherein the organic solvent is acetonitril or *tert*-butyl methyl ether.

13. The process according to any of claims 11 and 12 wherein a  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salt of omeprazole is obtained.

14. The process according to any of claims 11 and 12 wherein a  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salt of esomeprazole is obtained.

15. A pharmaceutical composition comprising the  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salt of omeprazole or esomeprazole according to any of claims 1 to 10 as active ingredients in association with pharmaceutically acceptable excipients and optionally other therapeutic ingredients.

5 16. Use of the  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salt of omeprazole or esomeprazole according to any of claims 1 to 10 for the manufacture of a medicament for use in the treatment of gastric acid related condition.

10 17. A method for treatment of a gastric acid related condition which method comprised administering to a subject suffering from said condition a therapeutically effective amount of the  $\text{NHR}_1\text{R}_2\text{R}_3^+$  salt of omeprazole or esomeprazole according to any of claims 1 to 10.